Dexcom Inc banner

Economic Moat

Dexcom has a narrow economic moat

Patents covering Dexcom’s glucose-sensing technology make its products harder to copy. Connections to compatible insulin pumps also give some patients a practical reason to stay, because changing sensors can mean changing how their diabetes equipment works together. These protections limit competition without shutting out established rivals such as Abbott.

What protects Dexcom from competitors

Intangible Assets

Dexcom holds patents covering parts of the sensor and protective membrane that help it measure glucose beneath the skin. These rights prevent rivals from freely copying protected designs, requiring them to develop alternatives or obtain permission to use the technology.

High Switching Costs

Dexcom sensors work with compatible insulin pumps that automatically adjust insulin delivery, making the sensor part of a patient’s treatment setup. For patients whose equipment does not support a rival sensor, switching can require equipment or software changes rather than simply buying another brand.

What could weaken Dexcom's moat

Intangible Assets

Rivals bypass protected designs

A rival that develops equally effective sensors without using Dexcom’s patented designs could compete without being held back by those patents.

High Switching Costs

Broader rival pump compatibility

Further expansion of Abbott sensor compatibility across insulin pumps could let more Dexcom users switch without replacing equipment or disrupting automated insulin delivery.